

DECLARATION

I, Zeh Akiy Zacheaus (student number: 0705645J) am a post-graduate student registered for the degree / programme Msc Med in Epidemiology and Biostatistics in the Wits School of Public Health.

I am submitting this research report as partial fulfillment; to the award of the fore mentioned degree and hereby declare the following:

- I confirm that the work submitted for the above course and module, is my own work, except where I have stated otherwise
- I have followed the required conventions in referencing the thoughts and ideas of others

Signature:

Date:

DEDICATION

This work is gratefully dedicated to my late father Mr. Akiy Buh Donatus and all my nephews and nieces; Javea, Denzel, Mbong, Angel and Afoh.

Zeh Akiy Zacheaus

January 2007

ACKNOWLEDGEMENT

First of all I will like to praise and thank my God for making it possible for me to be able to go through with this work and for providing every thing I needed in the past year.

Also, I would like to express my sincere gratitude and thanks to my sponsors, those who provided all the finance for my schooling my sisters Caroline and her husband Mbi, Irene and her husband Carlson. I could never pay them back.

Next, my gratitude to the Themba Lethu Clinic and Right to Care for permitting and providing data on patients on ARV roll-out at the clinic, data used in this study. I hope and belief the result of this study will benefit all parties.

I have been very fortunate to have as my supervisor Professor Patrick MacPhails who in spite of his function and extremely busy schedule provided me with superb supervision, guidance, knowledge and support while motivating and keeping up with my weaknesses. I thank my lecturers, Mr. Edmore Marinda who guided me on some of the statistical issues, Dr. Ronel Kellerman, Prof. Klipstein Kerstin, Dr. Renay Weiner, Dr. Tint and all the staff of the Wits School of Public Health Lindy M., Lawrence P. and others for moral and educational support.

I will also without doubt express sincere thanks to Babatyi Malope, Maihri Maskew and Samuel Oti whose zeal to share knowledge was vital to the completion of this study.

Finally, my special thanks to my mother Mrs. Akiy Magdalene, brothers and sisters and all my friends whose criticisms and expectations pushed me to do more than my best.

TABLE OF CONTENTS

Declaration.....	I
Dedication.....	II
Acknowledgement.....	III
Table of Contents.....	IV
List of Figures.....	V
List of Tables.....	VI
List of Appendices.....	VII
List of Abbreviations.....	VIII
Abstract.....	IX
Chapter One: General Introduction.....	1
Chapter Two: Methodology	17
Chapter Three: Results	30
Chapter Four: Discussion	51
Chapter Five: Conclusion and Recommendations	58
References	60
Appendix A.....	
Appendix B	
Appendix C	
Appendix D.....	
Appendix E.....	

LIST OF FIGURES

Figure 3.1:	Percentage distribution of Patients by Gender	30
Figure 3.2:	percentage distribution of deaths by TB Status.....	31
Figure 3.3:	Distribution of weight by TB group.....	37
Figure 3.4:	Distribution of hemoglobin counts by TB group.....	38
Figure 3.5:	KM Survival curve for deaths by person days in cohort.....	46
Figure 3.6:	Survival curve in attaining +2kg in the cohort.....	46
Figure 3.7:	Smooth hazard estimates of weight gain.....	47
Figure 3.8:	Survival curve showing proportion of viral load ≤ 400	47
Figure 3.9:	survival curve those who stayed in the cohort.....	48

LIST OF TABLES

Table 3.1:	Numbers and proportions for some variables in the cohort...	32
Table 3.2:	Distribution of Demographic categories by TB status.....	33
Table 3.3:	Comparing means of first observations by TB Status-ttest distribution.....	35
Table 3.4:	Distribution of outcome means by Months After Initiation of ARV.....	36
Table 3.5:	Bivariate Analysis of TB status Risk Ratio of dying by Possible Confounders.....	39
Table 3.6:	Bivariate Analysis of TB RR for Loss to Follow up by Possible Confounders.....	40
Table 3.7:	Regression Coefficients for relationship of Outcome variables with Time.....	41
Table 3.8:	Incidence rate and ratio of failures in specified end point Variables.....	44
Table 3.9:	Multivariate survival analysis for RR of outcomes considering demographics	49

LIST OF APPENDICES

Appendix A: Ethics Approval Certificate

Appendix B: Graphs of Summary and Survival statistics including Log rank test of equality of survival curves

Appendix C: Flow chart at the Themba Lethu Clinic

Appendix D: Data collection tools at Themba Lethu

Appendix E: Standard procedure form for using data from Themba Lethu Clinic

Appendix F: Signed approval form to use data from Themba Lethu Clinic

LIST OF ABBREVIATIONS

AIDS	Acquired Immune Deficiency Syndrome.
ALT	Alanine Aminotransferase.
ART	Antiretroviral Therapy.
ARV	Antiretroviral.
AST	Aspartate Aminotransferase.
BMI	Body Mass Index.
CD ₄	Glycoprotein surfaces helper T cells act as receptor for HIV.
CDC	Centers for Disease Control and Prevention.
CHRU	Clinical HIV Research Unit.
CI	Confidence Interval.
CSV	Comma Separated Value.
HAART	Highly Active Antiretroviral Therapy.
Hb	Hemoglobin.
HIV	Human Immunodeficiency Virus.
HJH	Helen Joseph Hospital.
KM	Kaplan Meier.
LFT	Liver Function Test.
MTB	Mycobacterium tuberculosis.
PEPFAR	President's Emergency Plan for AIDS Relief.
RR	Rate Ratio.
SAS	Statistical Analysis Software.
SSA	Sub-Saharan Africa.
TB	Tuberculosis.
TB-	Tuberculosis Negative.
TB+	Tuberculosis Positive.
TLC	Themba Lethu Clinic.
UNAIDS	Joint United Nations Programme on HIV/AIDS.
USAID	United States Agency for International Development.
WHO	World Health Organization.

ABSTRACT

Introduction: The burden of disease due to HIV/AIDS and tuberculosis remains great for many countries around the world. Continuing attention must be devoted to these epidemics if we ever hope to one day contain their devastating effects on humankind. The objective of this study is to; to evaluate and compare cohort treatment outcomes of HIV infected TB patients and HIV infected non-TB patients treated with HAART at the Themba Lethu Clinic between 1st April 2004 and 1st April 2007. To measure outcomes in CD₄, viral load, hemoglobin, liver function tests, weight, BMI, loss to follow up and death and to compare this outcomes between HIV patients who have had TB and HIV patients who have never had TB.

Materials and Methods: information collected of patients for three years shall be used to carry out analysis. A total of 5818 patients were included in the cohort sample. 19.23% (1,048) of the patients had been diagnosed with TB at some point in time while 80.77% (4,770) had never been diagnosed with TB. Mean baseline CD₄ cell counts were 113.47cells/mm³ for non TB patients and 88.85cells/mm³ for those who have ever had TB. This baseline CD₄ counts are considered 2 months prior to ARV start and 1 month post the start of ARV. Baseline means for weight, BMI, AST and ALT were also taken into consideration by the two patient groups. Clinical out come was assessed and evaluated by comparing incidence of designated end points either as survival or failures. Incidence of deaths and loss to follow up was also compared in the two groups of patients.

Results: Among HIV non TB patients, incidence rate of them having CD₄ counts greater than 200 was at 36.47 persons per 10000 person days while for the patients who had been diagnosed with TB incidence of CD₄ rising to above

200 was lower at 34.19 persons per 10000 person days. A rate ratio of 0.94 (95% CI 0.85 - 1.03) showed no true difference in the two groups. When looking at deaths in the two groups of patients, incidence in those who had TB was 3.84 deaths per 100 patient years and 4.16 deaths per 100 patient years for the non TB group with RR 0.93 and CI 0.66 - 1.28. Differences in incidence and outcomes were noticed in Hb gain, weight and BMI change, Liver function test changes over time and loss to follow up “defaulters”. Survival curves were modeled to show trend of change and log rank test were used to ascertain equality of survival curves. Where log rank p. values < 0.05 were noticed among survival curves of weight, BMI, AST, ALT, Hb and Loss to follow up. This again showed differences in weight, BMI, hemoglobin, AST, ALT and loss to follow up while no statistical differences were recognized between the two groups of patients when considering changes in CD₄, deaths and Viral load over time as log rank test failed to reject the null hypothesis of similar curves.

Conclusion: Data indicated that similarity and differences between HIV TB patients and HIV non TB patients could vary along certain outcomes. But one sure point is both groups of patients had an equal chance of staying alive when properly treated with ARV/HAART.